Large Skin Ulcer and Delayed Wound Healing around a Colostomy in a Patient with Metastatic Colorectal Cancer Receiving Vascular Endothelial Growth Factor Receptor-2 Inhibitor Therapy

Ramucirumab is an antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGF)-2 that has been approved for second-line treatment of patients with metastatic colorectal cancer. VEGF-targeted therapy has various distinctive adverse effects owing to its antitumour effects. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Taira, Koichi, Nadatani, Yuji, Hirano, Shinji, Maeda, Kiyoshi, Fujiwara, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547261/
https://www.ncbi.nlm.nih.gov/pubmed/31182953
http://dx.doi.org/10.1159/000500412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547261/
https://www.ncbi.nlm.nih.gov/pubmed/31182953
http://dx.doi.org/10.1159/000500412

Ejemplares similares